CareDx(CDNA) - 2024 Q3 - Earnings Call Presentation

Financial Performance - Total revenue for Q3 2024 was $82.9 million, a 23% increase year-over-year[9] - Testing Services volume reached 44,600 tests, a 16% increase year-over-year[9] - The company achieved a GAAP net loss of $7.4 million, a non-GAAP net income of $8.0 million, and a positive adjusted EBITDA of $6.9 million[9] - The company's cash, cash equivalents, and marketable securities stand at approximately $241 million with no debt[9] - The company raised its annual revenue guidance to $327 to $331 million and adjusted EBITDA to a gain of $18 to $22 million[10] Business Updates - CMS reaffirmed Medicare coverage for AlloSure® and AlloMap® Testing[10] - The DOJ concluded its investigation into CareDx with no finding of wrongdoing[11] - QTYPE now features single bead antigen resolution for rapid deceased donor typing[12] - The company launched an Early Access Program with Dovetail Genomics, introducing innovative haplotyping technology to HLA labs[11] Future Targets - The company is targeting $500 million in revenue by 2027[18] - The company is targeting a 20% adjusted EBITDA by 2027[18]